AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer

Adamski, 2001, A quide to 17β-hydroxysteroid dehydrogenases, Mol. Cell. Endocrinol., 171, 1, 10.1016/S0303-7207(00)00383-X Akhmedkhanov, 2001, Role of exogenous and endogenous hormones in endometrial cancer, Ann. N. Y. Acad. Sci., 943, 296, 10.1111/j.1749-6632.2001.tb03811.x American Cancer Society, 2005. Cancer Facts and Figures 2003. Bardin, 2004, Loss of ERβ expression as a common step in estrogen-dependent tumor progression, Endocr. Relat. Cancer, 11, 537, 10.1677/erc.1.00800 Desmond, 2003, The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxigenase-dependent antineoplastic actions of nonsteroidal anti-inflamatory drugs, Cancer Res., 63, 505 Dufort, 1999, Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase, Endocrinology, 140, 568, 10.1210/en.140.2.568 Flötotto, 2001, Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer, Horm. Metab. Res., 33, 451, 10.1055/s-2001-16936 Henderson, 2000, Hormonal cancerogenesis, Carcinogenesis, 21, 427, 10.1093/carcin/21.3.427 Husen, 2000, Differential expression of 17beta-hydroxysteroid dehydrogenases types 2 and 4 in human endometrial epithelial cell lines, J. Mol. Endocrinol., 24, 135, 10.1677/jme.0.0240135 Inoue, 2001, Current molecular aspects of the carcinogenesis of the uterine endometrium, Int. J. Gynecol. Cancer, 11, 339, 10.1046/j.1525-1438.2001.01046.x Institute of Oncology, Ljubljana, 2005. Cancer Incidence in Slovenia 2002. Report No.44. International Agency for Research on Cancer, 2005. Globocan 2002. Kaku, 2001, Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome, Cancer Lett., 167, 39, 10.1016/S0304-3835(01)00462-1 Lanišnik Rižner, 2003, Role of human type 3 3α-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cells, Endocrinology, 144, 2922, 10.1210/en.2002-0032 Lindberg, 2003, Estrogen receptor ERβ reduces ERα regulated gene transcription, supporting a ying-yang relationship between ERα and ERβ, Mol. Endocrinol., 17, 203, 10.1210/me.2002-0206 Midnich, 2004, The role of 17beta-hydroxysteroid dehydrogenases, Mol. Cell. Endocrinol., 218, 7, 10.1016/j.mce.2003.12.006 Mote, 1999, Colocalization of progesterone receptor A and B by dual immunofluorescence histochemistry in human endometrium during the menstrual cycle, J. Clin. Endocrinol. Metab., 84, 2963, 10.1210/jc.84.8.2963 Nakajima, 2003, Expression of 20α-hydroxysteroid dehydrogenase mRNA in human endometrium and decidua, Endocr. J., 50, 105, 10.1507/endocrj.50.105 Nishizawa, 2000, Close kinship of human 20α-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes, Genes Cells, 5, 111, 10.1046/j.1365-2443.2000.00310.x Pelletier, 1999, Immunocytochemical localization of type 5 17β-hydroxysteroid dehydrogenase in human reproductive tissues, J. Histochem. Cytochem., 47, 731, 10.1177/002215549904700602 Peltoketo, 1999, 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes, J. Mol. Endocrinol., 23, 1, 10.1677/jme.0.0230001 Penning, 2000, Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex steroids, Biochem. J., 351, 67, 10.1042/0264-6021:3510067 Penning, 1997, Molecular endocrinology of hydroxysteroid dehydrogenases, Endocr. Rev., 18, 281, 10.1210/er.18.3.281 Penning, 2003, Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action, Hum. Reprod. Update, 9, 193, 10.1093/humupd/dmg022 Persson, 2000, Estrogens in the causation of breast, endometrial and ovarian cancers—evidence and hypothesis from epidemiological findings, J. Steroid Biochem. Mol. Biol., 74, 357, 10.1016/S0960-0760(00)00113-8 Sasaki, 2001, Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer, Cancer Res., 61, 97 Sasano, 2000, 17β-Hydroxysteroid dehydrogenase in human breast and endometrial carcinoma, Oncology, 59, 5, 10.1159/000055281 Steckelbroeck, 2004, Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action, J. Biol. Chem., 279, 10784, 10.1074/jbc.M313308200 Utsunomiya, 2001, The analysis of 17β-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma, Clin. Endocrinol. Metab., 86, 3436, 10.1210/jc.86.7.3436 Utsunomiya, 2003, The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17β-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma, Clin. Endocrinol., 58, 696, 10.1046/j.1365-2265.2003.01766.x Weihua, 2000, Estrogen receptor (ER) β, a modulator of ERα in the uterus, PNAS, 97, 5936, 10.1073/pnas.97.11.5936 Yang, 2001, Stromal PRs mediate induction of 17β-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2, Mol. Endocrinol., 15, 2093, 10.1210/me.15.12.2093 Zhang, 2000, Characterization of a human 20α-hydroxysteroid dehydrogenase, J. Mol. Endocrinol., 25, 221, 10.1677/jme.0.0250221